arrow
M

Michele Orditura

fondazione irccs istituto nazionale tumori milan
H指数:54
被引数:9,203
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Differential methylation of circulating free DNA assessed through cfMeDiP as a new tool for breast cancer diagnosis and detection of BRCA1/2 mutation
2024-10-151
OAAI
Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP study
BREAST
IF7.9
2024-10-010
OAAI
Editorial: Heterogeneity in breast cancer: clinical and therapeutic implications
2024-02-262
OAAI
Post-Irradiation Breast Angiosarcoma: All the Possible Treatments and Electrochemotherapy. Case Report and Literature Review
2024-01-182
OAAI
Serum thymidine kinase activity in patients with HR- positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial

接受ribociclib和来曲唑治疗的HR阳性/HER2-negative晚期乳腺癌患者的血清胸苷激酶活性: 前瞻性BioItaLEE试验的结果

2023-06-015
PRE
Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis
2022-11-2611
OAAI
The Innate Immune Microenvironment in Metastatic Breast Cancer
2022-10-115
OAAI
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
2022-05-0711
OAAI
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients

心脏肿瘤单元对预防癌症患者心血管事件的影响

2022-04-019
OA
Serum thymidine kinase 1 activity in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first-line with ribociclib (R) and letrozole (L) in the BioItaLEE trial
2021-09-013
OAAI
Prognostic impact of progesterone receptor levels in luminal-like Her2-early breast cancer patients: A retrospective analysis
2020-09-010
OAAI
Efficacy of the triple combination of Estrogen Receptor, CDK4/6 and PI3K pathway inhibitors in ex-vivo models of breast cancer

雌激素受体、CDK4/6和PI3K通路抑制剂三联在乳腺癌离体模型中的疗效

2020-09-010
OAAI
Prognostic value of high mesenchymal-epithelial transition factor gene (MET) expression in patients with estrogen receptor positive (ER plus ), human epidermal growth factor receptor negative (HER2-) early breast cancer
2020-09-010
OAAI
BioItaLEE: Comparative biomarker analysis of liquid biopsies and paired tissue samples of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC)
2020-05-012
OAAI
Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania 'Luigi Vanvitelli'
2020-01-0113
OAAI
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial
2019-09-0156
OAAI
Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)
2018-06-1447
PREAI
Taselisib enhances effects of anti-microtubule chemotherapic agents in phosphatidylinositol 3-kinase (PI3Kα) mutant breast cancer cell lines
2016-10-010
OAAI
Neutrophil to lymphocyte ratio is a predictor of outcome in metastatic pancreatic cancer patients (MPC) treated with nab-paclitaxel and gemcitabine
2016-10-010
OAAI
Efficacy of sequential treatment with first, second and third generation EGFR inhibitors and role of Hedgehog pathway in the acquisition of resistance in in vivo NSCLC models
2016-10-010
OAAI